Cure My Disease

Don't miss your cure!

 Log in / Sign up

New PAH drug IKT-001 moves to Long-Term safety check

NCT ID NCT07632898

Not yet recruiting Disease control Sponsor: Inhibikase Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is checking the long-term safety of a daily pill called IKT-001 for people with pulmonary arterial hypertension (PAH), a serious lung condition. About 484 adults who have already completed an earlier IKT-001 study will take the drug for an extended period. Researchers will track side effects and also measure how far patients can walk in 6 minutes and a heart stress marker in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
IKT-001 (tablet taken by mouth once daily)
What this could lead to
If successful, this could confirm that IKT-001 is safe enough for long-term use in managing pulmonary arterial hypertension.
What could go wrong
This is an open-label extension study with no placebo group, so results may be less reliable. It only includes people who tolerated IKT-001 before, which may not reflect the broader patient population.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary arterial hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY ARTERIAL HYPERTENSION (PAH)

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.